SCHEMBL1614224

SCHEMBL1614224

COCCOCCOc1cnc(N)nc1-c1c[nH]c2ccc(C#CC3(O)CCCC3)cc12

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAP3K14 Q99558 8/20 0.67
PIKFYVE Q9Y2I7 4/20 0.67
PAK4 O96013 4/20 0.41
PAK6 Q9NQU5 2/20 0.41
PAK5 Q9P286 2/20 0.41
PAK1 Q13153 1/20 0.41
PAK2 Q13177 1/20 0.41
PKN1 Q16512 1/20 0.41
CHUK O15111 1/20 0.41
CLK1 P49759 5/20 0.39
TTBK1 Q5TCY1 2/20 0.39
CDK5 Q00535 3/20 0.38
CDK5R1 Q15078 3/20 0.38
PRKX P51817 1/20 0.35
TAOK1 Q7L7X3 1/20 0.35
TSSK3 Q96PN8 1/20 0.35
TSSK1B Q9BXA7 1/20 0.35
TAOK3 Q9H2K8 1/20 0.35
TAOK2 Q9UL54 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1614473 0.98 MAP3K14 (0.70) MAP3K14PIKFYVEPAK4PAK6PAK5
SCHEMBL1611663 0.96 MAP3K14 (0.70) MAP3K14PIKFYVEPAK4PAK6PAK5
SCHEMBL1613152 0.90 MAP3K14 (0.67) MAP3K14PIKFYVEPAK4PAK6PAK5
SCHEMBL1612966 0.89 MAP3K14 (0.56) MAP3K14PIKFYVEPAK4CHUKCLK1
SCHEMBL1613636 0.86 MAP3K14 (0.51) MAP3K14PIKFYVEPAK4PAK6PAK5
SCHEMBL1613794 0.85 MAP3K14 (0.53) MAP3K14PIKFYVEPAK4PAK6PAK5
SCHEMBL1614133 0.83 MAP3K14 (0.51) MAP3K14PIKFYVEPAK4PAK6PAK5
SCHEMBL1614177 0.83 MAP3K14 (0.51) MAP3K14PIKFYVECHUKCLK1TTBK1
SCHEMBL12743305 0.81 MAP3K14 (0.60) MAP3K14PIKFYVECLK1CDK5CDK5R1
SCHEMBL1613250 0.81 MAP3K14 (0.57) MAP3K14PIKFYVEPAK4CHUKCLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2315751-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS Amgen Inc. (US) 2011-05-04 EP disclosed
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2011-04-14 US disclosed
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2011-04-14 US disclosed
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2011-04-14 US disclosed
WO-2009158011-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2009-12-30 WO disclosed
WO-2009158011-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS NFKBIA, MAP3K1, MAP3K2 MAP3K14 17/4885PIKFYVE 126/4885PAK4 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.